This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03410/identifier/pdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB03410/identifier/pubchem-compound/
n15http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB03410/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB03410/identifier/drugbank/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03410
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n12:DB03410 n15:DB03410
dcterms:title
4-hydroxycoumarin
adms:identifier
n8:14101 n9:46508501 n10:DB03410 n13:4HC
n3:synonym
4-Hydroxy-1-Benzopyran-2-One
n3:synthesisReference
Nasri W. Badran, "Microcrystalline 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin (warfarin) and methods of making." U.S. Patent US4113744, issued April, 1960.
n5:hasConcept
n6:M0188047
n3:IUPAC-Name
n4:271B4571-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4577-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4576-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4573-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4574-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4575-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B456F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4570-363D-11E5-9242-09173F13E4C5 n4:271B456D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B456E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B457D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B457E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4578-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4579-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B457B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B457A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B457C-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
1076-38-6
n3:Bioavailability
n4:271B4583-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4585-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4586-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4587-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4582-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4581-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4584-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4572-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B457F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4580-363D-11E5-9242-09173F13E4C5